niraparib
FDA Approves FoundationOne Liquid CDx to Select BRCA-Mutated mCRPC Patients for Janssen's Akeega
The FDA expanded the label to include the blood-based sequencing test as well as the tissue-based CDx, which was already approved to select patients for Akeega.
GSK, Ivy Brain Tumor Center to Begin Phase III Trial of Zejula in MGMT Unmethylated Glioblastoma
The Phase III trial was initiated after researchers reported promising results from a Phase 0/II trial of Zejula in this setting.
J&J Oncology Revenues Jump 12 Percent in Q3
The firm touted sales gains for Carvykti and highlighted regulatory updates for Akeega, Balversa, and Rybrevant in Q3.
Janssen Nets FDA OK for Akeega With Foundation Medicine CDx in BRCA1/2-Mutated Prostate Cancer
The PARP inhibitor and hormone therapy-containing drug, given with prednisone, benefited metastatic castration-resistant prostate cancer patients more than abiraterone acetate plus prednisone.
J&J Highlights Forthcoming Precision Rx Approvals, Indication Expansions in Multiple Myeloma
Premium
During a call to discuss Q2 earnings, J&J CEO Joaquin Duato discussed the company's aspirations to develop a treatment for every line of therapy for multiple myeloma patients.